FDA Phasing In Restructuring Of Drug Office; Move To White Oak Postponed
FDA is proceeding with the restructuring of the Office of New Drugs ahead of a formal switch to the new organization in September
You may also be interested in...
The Life Sciences-Biodefense lab complex would remain on schedule for completion in FY 2014, but communications and logistical buildings included in the campus master plan would be on hold.
CDER's Office of New Drugs reorganizes as rheumatology moves from analgesics to join allergy.
Divisions from FDA's Office of Pharmacoepidemiology & Statistical Science (OPaSS) are expected to relocate to the agency's new White Oak, Md. campus in mid-September